Business Wire

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first half of 2021, pending licensure in Japan. This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japan’s Ministry of Health Labour and Welfare (MHLW). Moderna has previously announced that the 30,000 participant Phase 3 clinical trial of mRNA-1273 at the 100 µg dose level in the U.S. is fully enrolled.

This follows Takeda’s recent announcement that it is establishing the capability to manufacture Novavax’ COVID‑19 vaccine candidate at its facilities in Japan to provide long-term supply to the Japanese population. Takeda’s efforts to bring Moderna’s and Novavax’ COVID-19 vaccine candidates to Japan are supported by the MHLW and the Japan Agency for Medical Research and Development (AMED).

“Takeda is collaborating with the Japanese Government and vaccine developers to provide rapid and sustained access to COVID-19 vaccines in Japan,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “We have chosen to work with Novavax and Moderna, both of which have promising vaccine candidates, and will continue to support the global response to COVID-19 through R&D efforts across Takeda.”

Under the terms of the new agreement with the MHLW and Moderna, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing 50 million doses of Moderna’s COVID-19 vaccine candidate in Japan. Moderna will provide finished product and will support Takeda with its development and regulatory efforts.

About Takeda’s COVID-19 Efforts

Takeda is taking a comprehensive approach to treat and prevent COVID-19 through multiple activities and partnerships focused on advancing development of a variety of potential therapies and vaccines. Takeda co-founded the CoVig-19 Plasma Alliance and joined forces with other leading plasma companies to develop and manufacture investigational hyperimmune immunoglobulin medicine in the global fight against COVID-19. The Alliance is also participating in The Fight Is In Us coalition and related convalescent plasma donation campaign. The company is also assessing existing Takeda products and those in development for activity against the COVID-19 virus, and has joined the COVID R&D Alliance, the IMI Care Alliance and the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership. Takeda has partnered with the Government of Japan, Novavax and Moderna, to help accelerate the availability of a COVID-19 vaccine. We are leveraging our extensive and well-established global manufacturing and supply capabilities and building upon our existing influenza pandemic preparedness efforts in Japan. Takeda supports our partners and alliances in a shared goal to rapidly discover, develop and deliver effective treatments and vaccines for COVID-19 and ensure preparedness for future pandemics.

Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For the past 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, Zika and norovirus. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visitwww.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Takeda Pharmaceuticals
Media in Japan
Kazumi Kobayashi
+81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

Media Outside Japan
Rachel Wiese
+1 917-796-8703
rachel.wiese@takeda.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Finsbury Glover Hering and Sard Verbinnen & Co. Complete Merger, Creating Global Strategic Communications Leader1.12.2021 12:30:00 CET | Press release

Following their announcement on October 13, 2021, Finsbury Glover Hering and Sard Verbinnen & Co. (“SVC”) have completed their merger to create the world’s leading strategic communications firm advising clients in navigating critical opportunities and challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005402/en/ The firm brings together over 1,000 communications professionals, operating from 25 offices in Asia, Europe, the Middle East and the United States, including its global headquarters in New York. The new firm is a leader in all aspects of strategic communications, including government affairs, corporate reputation, crisis management and transformation and change, as well as the leading force in financial communications worldwide. Its professionals have deep sector knowledge within rapidly growing industries, such as Health, Tech, Food and Agriculture and Renewable Energy, as well as expertise in Diversit

Wella Company Celebrates Its First Year as an Independent Company by Exceeding Growth Targets, Introducing Breakthrough Innovation and Broadening Leadership Capabilities1.12.2021 12:00:00 CET | Press release

Wella Company, a global leader in the $100 billion beauty industry, today celebrates its one-year anniversary as a stand-alone company. Wella Company has a top professional and retail hair, beauty tech and nail portfolio of iconic brands including Wella Professionals, Clairol, OPI, Nioxin, Sebastian Professional and ghd. The Company, founded in Germany in 1880, returned to independent operating status on December 1, 2020, led by global investment firm Kohlberg Kravis and Roberts (“KKR”) investing a majority-equity stake, which they have twice increased over the past year. Wella Company emerged in the midst of the global COVID-19 pandemic, during which almost the entire professional salon industry – the company’s core customer base – was in lockdown. Despite this challenging global environment, the company set its growth strategy, focused on building the operating foundation for stand-alone success, and hired nearly 1,100 people across the globe, including a roster of top beauty, retail

Pioneer Completes Acquisition of Kodoku Studios1.12.2021 10:59:00 CET | Press release

Pioneer Media Holdings Inc. (“Pioneer” or the “Company”) is pleased to announce that, further to its news release dated October 28, 2021, it has completed its acquisition of Kodoku Studios Limited (“Kodoku”). Kodoku is a studio based in London, England, in the business of developing and publishing NFT (or non-fungible token) games. Its current focus is “The Pit,” a platform for gamers to stake their NFTs, which also allows gamers to attempt to increase the inherent value of their NFTs through “NFT warfare” in a “player vs. player” (PVP) gaming arena, anticipated to launch December 3, 2021. Hewie Rattray, CEO of Kokoku commented, “I am positively thrilled by the acquisition of Kodoku by Pioneer. We relish the opportunity to exercise our vision in the NFT gaming market under the guidance of such an innovative company. We eagerly anticipate unifying with the Pioneer trajectory as we push the frontiers of the metaverse to new limits.” In consideration of all of the securities of Kodoku, th

ATG to Use Ethical Hackers to Rein in Cybersecurity Challenges in Partnership With YesWeHack1.12.2021 10:00:00 CET | Press release

YesWeHack, Europe’s leading bug bounty platform has partnered with Sweden headquartered ATG, to identify potential vulnerabilities on its exposed assets. ATG provides quality excitement and entertainment through horse betting, sports betting and casino games for approximately 1.4 million customers. ATG is constantly evolving to meet new technology demands, increased data access, faster connections, and new digital channels. It is at the forefront of using digital technology to offer content-rich, personalised, and constantly available entertainment while meeting stricter regulation, digitalisation, and higher customer demands. Like other industries that retain extensive customer data, the sports betting and gambling industry is particularly vulnerable to cyber threats. In addition to the games themselves, ATG maintains databases that contain a wealth of private and financial information. It has payment systems and apps that hackers can target. Meanwhile, one of the most significant cha

Nordic Enterprises Embrace Cloud Services to Improve Customer Experience1.12.2021 10:00:00 CET | Press release

Enterprises in the Nordic region are increasing their spending on public cloud services and digital transformation to improve customer experiences, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™Public Cloud – Services & Solutions Report for the Nordics finds enterprises in the region also increasing cloud spending to expand their product and service portfolios across the globe. In response, public cloud service providers are focused on improving their digital transformation advisory services. Cloud spending in the Nordics has increased across all industry verticals over the last five to six quarters. “Enterprises in the Nordic region have embraced the cloud and emerging digital technologies to become more cost effective and enhance customer experience,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Companies are also looking for

Amazon Investing in 274 Renewable Energy Projects Globally, Adds 18 New Projects in Europe and U.S.1.12.2021 09:01:00 CET | Press release

Amazon (NASDAQ: AMZN) today announced 18 new utility-scale wind and solar energy projects across the U.S., Finland, Germany, Italy, Spain, and the U.K., totaling 5.6 gigawatts (GW) of procured capacity to date in 2021. Amazon now has 274 renewable energy projects globally and is on a path to power 100% of its business operations with renewable energy by 2025—five years earlier than its original 2030 commitment. These new utility-scale wind and solar projects bring Amazon’s total committed renewable electricity production capacity to more than 12 GW and 33,700 gigawatt hours (GWh) when the projects become fully operational, or electricity output equivalent to powering more than 3 million U.S. homes for a year. The projects will supply renewable energy for Amazon’s corporate offices, fulfillment centers, and Amazon Web Services (AWS) data centers that support millions of customers globally. The projects will also help Amazon meet its commitment to produce the clean energy equivalent of t

Calastone Announces Strategic Partnership With Microsoft to Accelerate the Digital Transformation of Funds and Collective Investments1.12.2021 09:00:00 CET | Press release

Calastone, the largest global funds network, has signed a partnership agreement with Microsoft, which will see the firms collaborate on the use of cloud and distributed ledger technology to create market efficiency across the global investment funds industry. By combining Calastone’s network, technology and market experience, with Microsoft’s expertise and track record in delivering capital markets solutions in Microsoft Azure, the companies will drive new opportunities for collective investments worldwide. Calastone is leveraging its network as the foundation on which to enable the asset management industry to realise its digital transformation agenda. As investor requirements grow for accessible, low cost and innovative ways of investing, Calastone is applying the very latest technologies to build the next generation infrastructure for the distribution of investment funds. Calastone introduced DMI Fund Services, a suite of solutions that provides fund managers, administrators and dis

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom